tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Unusually active option classes on open August 7th
The FlyUnusually active option classes on open August 7th
6d ago
CCJ
PCG
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
PremiumCompany Announcements
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
6d ago
SRPT
Sarepta price target lowered to $35 from $37 at Oppenheimer
PremiumThe Fly
Sarepta price target lowered to $35 from $37 at Oppenheimer
7d ago
SRPT
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
PremiumRatings
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
7d ago
SRPT
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
PremiumRatings
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
7d ago
SRPT
Sarepta reports Q2 adjusted EPS 64c, consensus 49c
PremiumThe FlySarepta reports Q2 adjusted EPS 64c, consensus 49c
8d ago
SRPT
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
10d ago
SRPT
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
Premium
The Fly
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
17d ago
SRPT
Sarepta Therapeutics Appoints Michael Severino as CEO
PremiumCompany Announcements
Sarepta Therapeutics Appoints Michael Severino as CEO
17d ago
8K
SRPT
Sarepta appoints Severino as Chief Executive Officer
PremiumThe Fly
Sarepta appoints Severino as Chief Executive Officer
17d ago
SRPT
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
PremiumRatings
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
23d ago
SRPT
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
PremiumThe Fly
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
23d ago
DYN
SRPT
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
PremiumThe FlyTractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
1M ago
AMT
CNK
Sarepta price target lowered to $20 from $23 at Piper Sandler
Premium
The Fly
Sarepta price target lowered to $20 from $23 at Piper Sandler
1M ago
SRPT
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
Premium
The Fly
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
1M ago
SRPT
H.C. Wainwright says Sarepta news does not signal full approvals
PremiumThe Fly
H.C. Wainwright says Sarepta news does not signal full approvals
1M ago
SRPT
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
PremiumThe Fly
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
1M ago
SRPT
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
PremiumCompany Announcements
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
2M ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
2M ago
AZN
BMY
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
PremiumCompany AnnouncementsSRPT Expands Into Huntington’s Disease With New First-in-Human Trial
2M ago
SRPT
FDA issues draft guidance to help accelerated cell, gene therapies for patients
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2M ago
AZN
BMY
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
Premium
Ratings
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
3M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >